ClinicalTrials.gg
TerminatedNCT04860518HIBISCUSUpdated Jul 21, 2023Results posted

Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19

A Phase 2 interventional study of IFN beta-1a and Dexamethasone in Covid19, sponsored by Faron Pharmaceuticals Ltd. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-21.

Sponsored by Faron Pharmaceuticals Ltd · Phase 2, Interventional, and Other

Why this study was terminated
The decision is based on changes in the pandemic and further weakening of the recruitment that will not enable a completion of the study in any reasonable time

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing Interferon beta-1a in COVID-19 — 1 open to participants now, 1 under way, 1 of them phase 3. Interferon beta-1a · COVID-19.

Enrollment
12th of 12
7 · median 422
Started
2021
with 2 others
Phase 2
4 of 12
none open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Faron Pharmaceuticals Ltd

Among the 12 studies testing Interferon beta-1a in COVID-19, this one is the 12th largest by enrollment, is one of 3 that started in 2021, is one of 4 in phase 2, and was the 11th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 12 studies testing Interferon beta-1a in COVID-19 is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Interferon beta-1a in COVID-19, or all of them as a file.
02

Study summary

This double-blinded, randomized study is being conducted to see if the investigational new drug called FP-1201-lyo - intravenous Interferon beta-1a, hereafter IV IFN beta-1a, can help patients recover more quickly from COVID-19 and prevent worsening of the condition. To understand if IV IFN beta-1a can help treat patients with COVID-19, this study drug will be compared to dexamethasone.

Study subjects will be treated daily with IV IFN beta-1a 10 μg or IV dexamethasone for 6 consecutive days while hospitalized and will undergo daily assessments while in hospital for a maximum of 28 days. Study specific assessments will be collected at pre-dose Day 1 through Day 28 (PD and PIM assessments), in addition, clinical routine assessments will be utilized for safety and efficacy assessments.

03

Conditions studied

  • Covid19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Positive SARS-CoV-2 test by PCR (polymerase chain reaction) or other diagnostic method within the past 7 days
  3. Admission to hospital with respiratory symptoms of COVID-19 requiring hospital care and oxygen supplementation (≤ 8L/min)
  4. Respiratory symptom onset no more than 7 days prior to hospital arrival
  5. from the subject or the subject's personal legal representative or a professional legal representative must be available

Exclusion criteria

Exclusion Criteria:

  1. Unable to screen, randomize and administer study drug within 48 hours from arrival to hospital
  2. Systemic , baricitinib or tofacitinib (or other JAK-STAT signalling pathway inhibitors) therapy within 7 days prior to arrival to hospital or planned for the next days
  3. Known or to natural or recombinant IFN-beta-1a or its , or to dexamethasone or its excipients
  4. Currently receiving IFN-beta-1a therapy
  5. Home assisted ventilation (via tracheotomy or non-invasive) except for Continuous Positive Airway Pressure (CPAP) / Bilevel Positive Airway Pressure (BIPAP) used only for sleep-disordered breathing
  6. Participation in another concurrent interventional pharmacotherapy trial during the study period
  7. Decision to withhold life-sustaining treatment; patient not committed to full support (except DNR after cardiac arrest only)
  8. Woman known to be pregnant, lactating or with a positive pregnancy test (urine or serum test)
  9. Subject is not expected to survive for 24 hours
  10. Subject has liver failure ( grade C)
  11. Any clinical condition that in the opinion of the attending clinician or Investigator would present a risk for the subject to participate in the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    IV IFN beta-1a

    Patients receiving active drug: will receive two separate bolus injections one containing IFN-beta -1a and another injection containing Saline.

    Drug: IFN beta-1a

  • Active comparator
    IV Dexamethasone

    Patients receiving active comparator: will receive two separate bolus injections one containing saline and another injection containing Dexamethasone.

    Drug: Dexamethasone

Interventions

  • Treated daily with IFN beta-1a 10 μg as an IV bolus for 6 days while hospitalised

  • Treated daily with dexamethasone 6 mg as an IV bolus for 6 days while hospitalised

06

What researchers measure

Primary outcomes

  1. Clinical Status at Day 14 (First Day of Study Drug is Day 1) as Measured by WHO 9-point Ordinal Scale

    WHO 9-point ordinal scale: 0 - No detectable infection 1. - Not hospitalized, no limitations on activities 2. - Not hospitalized, limitation on activities 3. - Hospitalized, not requiring supplemental oxygen 4. - Hospitalized, requiring supplemental oxygen 5. - Hospitalized, on non-invasive ventilation or high flow oxygen devices 6. - Hospitalized, on invasive mechanical ventilation 7. - Hospitalized, on mechanical ventilation plus additional organ support: renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO) 8. - Death

    Time frame: Day 14

Secondary outcomes

  1. In-hospital Mortality at Day 28 and Day 90

    Percentage of participants per study group that die when in still hospital at Day 28 or Day 90 of the trial

    Time frame: Day 28 and Day 90

  2. Overall (All-cause) Mortality at Day 28 and Day 90

    Percentage of participants per study group that die within 28 days or 90 days from starting the study

    Time frame: Day 28 and Day 90

07

Results

Posted Oct 14, 2022
Limitations and caveats
No formal statistical hypotheses were analysed due the early termination of the study with only 5 dosed subjects.

Participant flow

Participant flow — Overall Study
MilestoneIV IFN Beta-1aIV Dexamethasone
Started34
Completed23
Not completed11
Withdrew: Screen failure, patient was not dosed11

Outcome measures

PrimaryClinical Status at Day 14 (First Day of Study Drug is Day 1) as Measured by WHO 9-point Ordinal Scale

WHO 9-point ordinal scale: 0 - No detectable infection 1. - Not hospitalized, no limitations on activities 2. - Not hospitalized, limitation on activities 3. - Hospitalized, not requiring supplemental oxygen 4. - Hospitalized, requiring supplemental oxygen 5. - Hospitalized, on non-invasive ventilation or high flow oxygen devices 6. - Hospitalized, on invasive mechanical ventilation 7. - Hospitalized, on mechanical ventilation plus additional organ support: renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO) 8. - Death

Time frame:
Day 14
Reported as:
Mean · units on a scale
Clinical Status at Day 14 (First Day of Study Drug is Day 1) as Measured by WHO 9-point Ordinal Scale
units on a scaleIV IFN Beta-1aIV Dexamethasone
Clinical Status at Day 14 (First Day of Study Drug is Day 1) as Measured by WHO 9-point Ordinal Scale2 ± 02 ± 0
SecondaryIn-hospital Mortality at Day 28 and Day 90

Percentage of participants per study group that die when in still hospital at Day 28 or Day 90 of the trial

Time frame:
Day 28 and Day 90
Reported as:
Count of participants · Participants
In-hospital Mortality at Day 28 and Day 90
ParticipantsIV IFN Beta-1aIV Dexamethasone
In-hospital Mortality at Day 28 and Day 9000
SecondaryOverall (All-cause) Mortality at Day 28 and Day 90

Percentage of participants per study group that die within 28 days or 90 days from starting the study

Time frame:
Day 28 and Day 90
Reported as:
Count of participants · Participants
Overall (All-cause) Mortality at Day 28 and Day 90
ParticipantsIV IFN Beta-1aIV Dexamethasone
Overall (All-cause) Mortality at Day 28 and Day 9000

Adverse events

Collected over Adverse events are collected from the signing of consent up to Day 28. AEs occurring after D28 were to be reported only if the Investigator considers there is a causal relationship with the study drug. All AEs up to D90, which lead to death, are reported as SAEs.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IV IFN Beta-1a0/2 (0%)0/2 (0%)1/2 (50%)
IV Dexamethasone0/3 (0%)2/3 (66.7%)2/3 (66.7%)
Most frequent serious events
Most frequent serious events
EventIV IFN Beta-1aIV Dexamethasone
dehydrationMetabolism and nutrition disorders0/21/3
head injuryInjury, poisoning and procedural complications0/21/3
Most frequent other events
Most frequent other events
EventIV IFN Beta-1aIV Dexamethasone
HyperglycemiaMetabolism and nutrition disorders1/20/3
HypokalemiaMetabolism and nutrition disorders1/20/3
HypnoatremiaMetabolism and nutrition disorders1/20/3
HypoxiaRespiratory, thoracic and mediastinal disorders1/20/3
Subdural hematomaInjury, poisoning and procedural complications0/21/3
SeizureNervous system disorders0/21/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)IV IFN Beta-1aIV DexamethasoneTotal
Mean60.0 ± 7.0055.8 ± 15.6957.6 ± 12.03
Sex: Female, Male
Sex: Female, Male(Participants)IV IFN Beta-1aIV DexamethasoneTotal
Female224
Male123
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IV IFN Beta-1aIV DexamethasoneTotal
Hispanic or Latino011
Not Hispanic or Latino336
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)IV IFN Beta-1aIV DexamethasoneTotal
Black or African American112
White and Other (not specified)022
White213
Eastern Cooperative Oncology Group (ECOG) status
Eastern Cooperative Oncology Group (ECOG) status(Participants)IV IFN Beta-1aIV DexamethasoneTotal
0: Able to carry out all normal activity without restriction336
2: Ambulatory and capable of all self-care but unable to carry out any work activities011
08

Study locations

4 sites
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Newton-Wellesley Hospital
    Newton, Massachusetts 02462, United States
  • Vanderbilt University School of Medicine
    Nashville, Tennessee 37232, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Apr 2022, 7 months.

Results were first posted in Oct 2022, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2021
First posted
Apr 27, 2021
StartActual
Aug 23, 2021
Primary completionActual
Apr 4, 2022
CompletionActual
Apr 4, 2022
Results first posted
Oct 14, 2022
Last update
Jul 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04860518
Lead sponsor
Faron Pharmaceuticals Ltd
Responsible party
Sponsor
First posted
Apr 27, 2021
Start date
Aug 23, 2021
Primary completion
Apr 4, 2022
Completion
Apr 4, 2022
Results posted
Oct 14, 2022
Last update
Jul 21, 2023

Study contacts

Daniel Talmor, MD MPH,
principal investigator · Deaconess Medical Center, Spokane, Washington
Adit Ginde, MD MPH,
principal investigator · University of Colorado School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion